<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="41880" whole_study_id="26575" phs="001472" v="2" p="1" createDate="2021-05-11T10:21:57-05:00" completedByGPADate="2021-06-22T09:15:07-05:00" modDate="2022-01-25T16:16:27-05:00" maxParentChildStudyModDate="2022-01-25T16:16:27-05:00" handle="TOPMed_WGS_ECLIPSE" num_participants="2400"><StudyInfo accession="phs001472.v2.p1" parentAccession="phs001472.v2.p1"><BioProject id="PRJNA414680" entrez_id="414680" type="bp_admin_access"/><BioProject id="PRJNA414681" entrez_id="414681" type="bp_data_submission"/><StudyNameEntrez>NHLBI TOPMed: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="No"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="cloud_for_sequence"/><StudyType22 name="whole_targ_genome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="Yes"><StudyType22 name="genotype_calls_from_sequence"/></StudyType21><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="tumor_normal"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>genotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>tumor_normal</StudyType><StudyType>genotype_calls_from_sequence</StudyType><StudyType>whole_genome</StudyType><StudyType>sra</StudyType></StudyTypes><SraStorages/><Funding>X01 HL134586</Funding></StudyInfo><Authority><ICs><IC id="12" name="NHLBI" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="EKS123" aid="2" auth="eRA" login="EKS123" fname="Edwin" mname="K" lname="Silverman" email="ED.SILVERMAN@CHANNING.HARVARD.EDU"><Role allow_direct_access="true">PI</Role><Organization>BRIGHAM AND WOMEN'S HOSPITAL</Organization></Person><Person nedid="0013114408" aid="1" auth="cit" login="ganw2" fname="Weiniu" mname="" lname="Gan" email="ganw2@mail.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person aid="8" auth="virtual" fname="Bj" lname="Stubbs" email="rebjh@channing.harvard.edu"><Role>PI_ASSIST</Role><Organization/></Person><Person nedid="0011276160" aid="1" auth="cit" login="thomsonal" fname="Alastair" mname="Alexander" lname="Thomson" email="alastair.thomson@nih.gov"><Role>PI_AA_DELEG</Role><Organization>NIH</Organization></Person><Person nedid="0014418323" aid="1" auth="cit" login="dzakpasuns" fname="Noble" mname="Senyo" lname="Dzakpasu" email="dzakpasuns@mail.nih.gov"><Role>PI_AA_DELEG</Role><Organization>NIH</Organization></Person><Person nedid="GROSSMANR" aid="2" auth="eRA" login="GROSSMANR" fname="ROBERT" mname="" lname="GROSSMAN" email="rgrossman1@uchicago.edu"><Role>PI_AA_DELEG</Role><Organization>UNIVERSITY OF ILLINOIS AT CHICAGOUNIVERSITY OF CHICAGO</Organization></Person><Person nedid="2002694957" aid="1" auth="cit" login="bastianica" fname="Carol" mname="Ann" lname="Bastiani" email="carol.bastiani@nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2002647128" aid="1" auth="cit" login="guptan11" fname="Neha" mname="" lname="Gupta" email="neha.gupta2@nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2001545300" aid="1" auth="cit" login="lic17" fname="Chengyuan" mname="" lname="Press" email="chanel.press@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>The TOPMed acknowledgement statement can be found at: https://topmed.nhlbi.nih.gov/acknowledgements. 
In addition, please include: &#8220;The ECLIPSE study (NCT00292552) was sponsored by GlaxoSmithKline.
The ECLIPSE investigators included:  Bulgaria: Y. Ivanov, Pleven; K. Kostov, Sofia. Canada: J. Bourbeau, Montreal; M. Fitzgerald, Vancouver, BC; P. Hernandez, Halifax, NS; K. Killian, Hamilton, ON; R. Levy, Vancouver, BC; F. Maltais, Montreal; D. O'Donnell, Kingston, ON. Czech Republic: J. Krepelka, Prague. Denmark: J. Vestbo, Hvidovre. The Netherlands: E. Wouters, Horn-Maastricht. New Zealand: D. Quinn, Wellington. Norway: P. Bakke, Bergen. Slovenia: M. Kosnik, Golnik. Spain: A. Agusti, J. Sauleda, P. de Mallorca. Ukraine: Y. Feschenko, V. Gavrisyuk, L. Yashina, Kiev; N. Monogarova, Donetsk. United Kingdom: P. Calverley, Liverpool; D. Lomas, Cambridge; W. MacNee, Edinburgh; D. Singh, Manchester; J. Wedzicha, London. United States: A. Anzueto, San Antonio, TX; S. Braman, Providence, RI; R. Casaburi, Torrance CA; B. Celli, Boston; G. Giessel, Richmond, VA; M. Gotfried, Phoenix, AZ; G. Greenwald, Rancho Mirage, CA; N. Hanania, Houston; D. Mahler, Lebanon, NH; B. Make, Denver; S. Rennard, Omaha, NE; C. Rochester, New Haven, CT; P. Scanlon, Rochester, MN; D. Schuller, Omaha, NE; F. Sciurba, Pittsburgh; A. Sharafkhaneh, Houston; T. Siler, St. Charles, MO; E. Silverman, Boston; A. Wanner, Miami; R. Wise, Baltimore; R. ZuWallack, Hartford, CT. 
ECLIPSE Steering Committee: H. Coxson (Canada), C. Crim (GlaxoSmithKline, USA), L. Edwards (GlaxoSmithKline, USA), D. Lomas (UK), W. MacNee (UK), E. Silverman (USA), R. Tal-Singer (Co-chair, GlaxoSmithKline, USA), J. Vestbo (Co-chair, Denmark), J. Yates (GlaxoSmithKline, USA).
ECLIPSE Scientific Committee: A. Agusti (Spain), P. Calverley (UK), B. Celli (USA), C. Crim  (GlaxoSmithKline, USA), B. Miller (GlaxoSmithKline, USA), W. MacNee (Chair, UK), S. Rennard (USA), R. Tal-Singer (GlaxoSmithKline, USA), E. Wouters (The Netherlands), J. Yates (GlaxoSmithKline, USA).&#8221;
</acknowledgement_statement><ic_specific_access_term>There is one consent group in ECLIPSE: Disease-Specific, COPD and Smoking, Methods (DS-CS-MDS-RD).  Use of this data is limited to studies of COPD and other smoking-related disorders. The full list of diseases or conditions for which smoking is considered to be a risk factor can be found at: www.copdgene.org/smoking-related-disorders. The institutional certification assured that data submission was compliant with, and limited to, local and federal policies, and Massachusetts state law; To the extent possible, consideration was given to individuals and groups for subsequent data sharing and are reviewed by the National Institutes of Health&#8217;s Data Access Committees.  Use of the data includes methods development research (e.g., development of software or algorithms).</ic_specific_access_term><DUC universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC><DUC_PDF universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="2734" CGType="cg_class_DS" title="Disease-Specific (COPD and Smoking, MDS, RD)" name="DS-CS-MDS-RD" dac_uid="56" dac_name="NHLBI" irb-approval-required="No"><Use-Restriction>Use of the data must be related to COPD and Smoking and related disorders.
Use of the data includes methods development research (e.g., development of software or algorithms).

Use of this data is limited to studies of COPD and other smoking-related disorders. The full list of diseases or conditions for which smoking is considered to be a risk factor can be found at: www.copdgene.org/smoking-related-disorders. Use of the data includes methods development research (e.g., development of software or algorithms). The institutional certification assured that data submission was compliant with, and limited to, local and federal policies, and Massachusetts state law; To the extent possible, consideration was given to individuals and groups for subsequent data sharing and are reviewed by the National Institutes of Health&#8217;s Data Access Committees.</Use-Restriction></ConsentGroup><ConsentGroup uid="2735" CGType="cg_class_EA" title="Exchange Area (MDS, RD)" name="EA-MDS-RD" dac_uid="56" dac_name="NHLBI" irb-approval-required="No"><Use-Restriction>Use by NHLBI WGS study investigators only.
There is one consent group: DS-CS-MDS-RD.
Use of this data is limited to studies of COPD and other smoking-related disorders. The full list of diseases or conditions for which smoking is considered to be a risk factor can be found at: www.copdgene.org/smoking-related-disorders. Use of the data includes methods development research (e.g., development of software or algorithms). The institutional certification assured that data submission was compliant with, and limited to, local and federal policies, and Massachusetts state law; To the extent possible, consideration was given to individuals and groups for subsequent data sharing and are reviewed by the National Institutes of Health&#8217;s Data Access Committees.
</Use-Restriction></ConsentGroup><ConsentGroupLinks><ConsentGroupLink cg_uid_from="2734"><StudyTo study_uid="37911" name="NHLBI Big Data Analysis Heart Failure Challenge Data Collection" accession="phs001991.v1"><ConsentGroupTo uid="4656" name="DS-CS-MDS-RD"/></StudyTo></ConsentGroupLink></ConsentGroupLinks><TrustedPartners><TrustedPartner trp_id="11" trp_db_name="NHLBI BioData Catalyst" trp_download_url="https://biodatacatalyst.nhlbi.nih.gov/resources/data" trp_help_url="https://biodatacatalyst.nhlbi.nih.gov/contact"><StudyFlags sam_with_min_meta="Yes" seq_data_to_ncbi="Yes" gen_phen_to_ncbi="Yes" has_out_ncbi_data="Yes"/></TrustedPartner></TrustedPartners></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="26575" whole_study_id="26575" phs="001472" v="1" p="1" createDate="2017-08-28T14:05:22-05:00" completedByGPADate="2017-09-05T12:10:35-05:00" modDate="2021-05-11T10:22:01-05:00" maxParentChildStudyModDate="2021-05-11T10:22:01-05:00" handle="TOPMed_WGS_ECLIPSE" num_participants="2400"><StudyInfo accession="phs001472.v1.p1" parentAccession="phs001472.v1.p1"><BioProject id="PRJNA414680" entrez_id="414680" type="bp_admin_access"/><BioProject id="PRJNA414681" entrez_id="414681" type="bp_data_submission"/><StudyNameEntrez>NHLBI TOPMed: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="No"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="cloud_for_sequence"/><StudyType22 name="whole_targ_genome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="Yes"><StudyType22 name="genotype_calls_from_sequence"/></StudyType21><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="tumor_normal"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>genotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>tumor_normal</StudyType><StudyType>genotype_calls_from_sequence</StudyType><StudyType>whole_genome</StudyType><StudyType>sra</StudyType></StudyTypes><SraStorages/><Funding>X01 HL134586</Funding></StudyInfo><Authority><ICs><IC id="12" name="NHLBI" is_funding_ic="true" is_admin_ic="true" primary="true"/></ICs><Persons><Person nedid="EKS123" aid="2" auth="eRA" login="EKS123" fname="Edwin" mname="K" lname="Silverman" email="ED.SILVERMAN@CHANNING.HARVARD.EDU"><Role allow_direct_access="true">PI</Role><Organization>BRIGHAM AND WOMEN'S HOSPITAL</Organization></Person><Person nedid="0013114408" aid="1" auth="cit" login="ganw2" fname="Weiniu" mname="" lname="Gan" email="ganw2@mail.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person aid="8" auth="virtual" fname="BJ" lname="Stubbs" email="rebjh@channing.harvard.edu"><Role>PI_ASSIST</Role><Organization/></Person><Person nedid="0011276160" aid="1" auth="cit" login="thomsonal" fname="Alastair" mname="Alexander" lname="Thomson" email="alastair.thomson@nih.gov"><Role>PI_AA_DELEG</Role><Organization>NIH</Organization></Person><Person nedid="0014418323" aid="1" auth="cit" login="dzakpasuns" fname="Noble" mname="Senyo" lname="Dzakpasu" email="dzakpasuns@mail.nih.gov"><Role>PI_AA_DELEG</Role><Organization>NIH</Organization></Person><Person nedid="GROSSMANR" aid="2" auth="eRA" login="GROSSMANR" fname="ROBERT" mname="" lname="GROSSMAN" email="rgrossman1@uchicago.edu"><Role>PI_AA_DELEG</Role><Organization>UNIVERSITY OF ILLINOIS AT CHICAGOUNIVERSITY OF CHICAGO</Organization></Person><Person nedid="2002694957" aid="1" auth="cit" login="bastianica" fname="Carol" mname="Ann" lname="Bastiani" email="carol.bastiani@nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2002647128" aid="1" auth="cit" login="guptan11" fname="Neha" mname="" lname="Gupta" email="neha.gupta2@nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2000452640" aid="1" auth="cit" login="chensh2" fname="Shu Hui" mname="" lname="Chen" email="shuhui.chen@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>The TOPMed acknowledgement statement can be found at: https://www.nhlbiwgs.org/acknowledgements. 
In addition, please include: &#8220;The ECLIPSE study (NCT00292552) was sponsored by GlaxoSmithKline.
The ECLIPSE investigators included:  Bulgaria: Y. Ivanov, Pleven; K. Kostov, Sofia. Canada: J. Bourbeau, Montreal; M. Fitzgerald, Vancouver, BC; P. Hernandez, Halifax, NS; K. Killian, Hamilton, ON; R. Levy, Vancouver, BC; F. Maltais, Montreal; D. O'Donnell, Kingston, ON. Czech Republic: J. Krepelka, Prague. Denmark: J. Vestbo, Hvidovre. The Netherlands: E. Wouters, Horn-Maastricht. New Zealand: D. Quinn, Wellington. Norway: P. Bakke, Bergen. Slovenia: M. Kosnik, Golnik. Spain: A. Agusti, J. Sauleda, P. de Mallorca. Ukraine: Y. Feschenko, V. Gavrisyuk, L. Yashina, Kiev; N. Monogarova, Donetsk. United Kingdom: P. Calverley, Liverpool; D. Lomas, Cambridge; W. MacNee, Edinburgh; D. Singh, Manchester; J. Wedzicha, London. United States: A. Anzueto, San Antonio, TX; S. Braman, Providence, RI; R. Casaburi, Torrance CA; B. Celli, Boston; G. Giessel, Richmond, VA; M. Gotfried, Phoenix, AZ; G. Greenwald, Rancho Mirage, CA; N. Hanania, Houston; D. Mahler, Lebanon, NH; B. Make, Denver; S. Rennard, Omaha, NE; C. Rochester, New Haven, CT; P. Scanlon, Rochester, MN; D. Schuller, Omaha, NE; F. Sciurba, Pittsburgh; A. Sharafkhaneh, Houston; T. Siler, St. Charles, MO; E. Silverman, Boston; A. Wanner, Miami; R. Wise, Baltimore; R. ZuWallack, Hartford, CT. 
ECLIPSE Steering Committee: H. Coxson (Canada), C. Crim (GlaxoSmithKline, USA), L. Edwards (GlaxoSmithKline, USA), D. Lomas (UK), W. MacNee (UK), E. Silverman (USA), R. Tal-Singer (Co-chair, GlaxoSmithKline, USA), J. Vestbo (Co-chair, Denmark), J. Yates (GlaxoSmithKline, USA).
ECLIPSE Scientific Committee: A. Agusti (Spain), P. Calverley (UK), B. Celli (USA), C. Crim  (GlaxoSmithKline, USA), B. Miller (GlaxoSmithKline, USA), W. MacNee (Chair, UK), S. Rennard (USA), R. Tal-Singer (GlaxoSmithKline, USA), E. Wouters (The Netherlands), J. Yates (GlaxoSmithKline, USA).&#8221;
</acknowledgement_statement><ic_specific_access_term>There is one consent group in ECLIPSE: Disease-Specific, COPD and Smoking, Methods (DS-CS-MDS-RD).  Use of this data is limited to studies of COPD and other smoking-related disorders. The full list of diseases or conditions for which smoking is considered to be a risk factor can be found at: www.copdgene.org/smoking-related-disorders. The institutional certification assured that data submission was compliant with, and limited to, local and federal policies, and Massachusetts state law; To the extent possible, consideration was given to individuals and groups for subsequent data sharing and are reviewed by the National Institutes of Health&#8217;s Data Access Committees.  Use of the data includes methods development research (e.g., development of software or algorithms).</ic_specific_access_term><DUC universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC><DUC_PDF universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="2734" CGType="cg_class_DS" title="Disease-Specific (Chronic Obstructive Pulmonary Disease, MDS, RD)" name="DS-COPD-MDS-RD" dac_uid="56" dac_name="NHLBI" irb-approval-required="No"><Use-Restriction>Use of the data must be related to Chronic Obstructive Pulmonary Disease and related disorders.
Use of the data includes methods development research (e.g., development of software or algorithms).

Use of this data is limited to studies of COPD and other smoking-related disorders. The full list of diseases or conditions for which smoking is considered to be a risk factor can be found at: www.copdgene.org/smoking-related-disorders. The institutional certification assured that data submission was compliant with, and limited to, local and federal policies, and Massachusetts state law; To the extent possible, consideration was given to individuals and groups for subsequent data sharing and are reviewed by the National Institutes of Health&#8217;s Data Access Committees.</Use-Restriction></ConsentGroup><ConsentGroup uid="2735" CGType="cg_class_EA" title="Exchange Area (MDS, RD)" name="EA-MDS-RD" dac_uid="56" dac_name="NHLBI" irb-approval-required="No"><Use-Restriction>Use by NHLBI WGS study investigators only.
There is one consent group: DS-COPD-MDS-RD.
Use of the data must be related to Chronic Obstructive Pulmonary Disease (COPD) and related disorders.
Use of the data includes methods development research (e.g., development of software or algorithms).
Use of this data is limited to studies of COPD and other smoking-related disorders. The full list of diseases or conditions for which smoking is considered to be a risk factor can be found at: www.copdgene.org/smoking-related-disorders. The institutional certification assured that data submission was compliant with, and limited to, local and federal policies, and Massachusetts state law; To the extent possible, consideration was given to individuals and groups for subsequent data sharing and are reviewed by the National Institutes of Health&#8217;s Data Access Committees.

</Use-Restriction></ConsentGroup><ConsentGroupLinks><ConsentGroupLink cg_uid_from="2734"><StudyTo study_uid="37911" name="NHLBI Big Data Analysis Heart Failure Challenge Data Collection" accession="phs001991.v1"><ConsentGroupTo uid="3893" name="DS-COPD-MDS-RD"/></StudyTo></ConsentGroupLink></ConsentGroupLinks><TrustedPartners><TrustedPartner trp_id="11" trp_db_name="NHLBI BioData Catalyst" trp_download_url="https://biodatacatalyst.nhlbi.nih.gov/resources/data" trp_help_url="https://biodatacatalyst.nhlbi.nih.gov/contact"><StudyFlags sam_with_min_meta="Yes" seq_data_to_ncbi="Yes" gen_phen_to_ncbi="Yes" has_out_ncbi_data="Yes"/></TrustedPartner></TrustedPartners></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>